Drug Approval | May 01, 2025
Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
Dr. Muthu was last associated with Mankind Pharma
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Subscribe To Our Newsletter & Stay Updated
